Risk factors associated with inappropriate empirical antimicrobial treatment in bloodstream infections. A cohort study
Copyright © 2023 Dietl, Boix-Palop, Gisbert, Mateu, Garreta, Xercavins, Badía, López-Sánchez, Pérez and Calbo..
Introduction: Bloodstream infections (BSI) are a major cause of mortality all over the world. Inappropriate empirical antimicrobial treatment (i-EAT) impact on mortality has been largely reported. However, information on related factors for the election of i-EAT in the treatment of BSI in adults is lacking. The aim of the study was the identification of risk-factors associated with the use of i-EAT in BSI. Methods: A retrospective, observational cohort study, from a prospective database was conducted in a 400-bed acute-care teaching hospital including all BSI episodes in adult patients between January and December 2018. The main outcome variable was EAT appropriation. Multivariate analysis using logistic regression was performed. Results: 599 BSI episodes were included, 146 (24%) received i-EAT. Male gender, nosocomial and healthcare-associated acquisition of infection, a high Charlson Comorbidity Index (CCI) score and the isolation of multidrug resistant (MDR) microorganisms were more frequent in the i-EAT group. Adequation to local guidelines' recommendations on EAT resulted in 91% of appropriate empirical antimicrobial treatment (a-EAT). Patients receiving i-EAT presented higher mortality rates at day 14 and 30 when compared to patients with a-EAT (14% vs. 6%, p = 0.002 and 22% vs. 9%, p < 0.001 respectively). In the multivariate analysis, a CCI score ≥3 (OR 1.90 (95% CI 1.16-3.12) p = 0.01) and the isolation of a multidrug resistant (MDR) microorganism (OR 3.79 (95% CI 2.28-6.30), p < 0.001) were found as independent risk factors for i-EAT. In contrast, female gender (OR 0.59 (95% CI 0.35-0.98), p = 0.04), a correct identification of clinical syndrome prior to antibiotics administration (OR 0.26 (95% CI 0.16-0.44), p < 0.001) and adherence to local guidelines (OR 0.22 (95% CI 0.13-0.38), p < 0.001) were identified as protective factors against i-EAT. Conclusion: One quarter of BSI episodes received i-EAT. Some of the i-EAT related factors were unmodifiable (male gender, CCI score ≥3 and isolation of a MDR microorganism) but others (incorrect identification of clinical syndrome before starting EAT or the use of local guidelines for EAT) could be addressed to optimize the use of antimicrobials.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
---|---|
Enthalten in: |
Frontiers in pharmacology - 14(2023) vom: 12., Seite 1132530 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Dietl, Beatriz [VerfasserIn] |
---|
Links: |
---|
Themen: |
Anti-bacterial agents-therapeutic use |
---|
Anmerkungen: |
Date Revised 02.11.2023 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
---|
doi: |
10.3389/fphar.2023.1132530 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM355673495 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM355673495 | ||
003 | DE-627 | ||
005 | 20231226064836.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.3389/fphar.2023.1132530 |2 doi | |
028 | 5 | 2 | |a pubmed24n1185.xml |
035 | |a (DE-627)NLM355673495 | ||
035 | |a (NLM)37063300 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Dietl, Beatriz |e verfasserin |4 aut | |
245 | 1 | 0 | |a Risk factors associated with inappropriate empirical antimicrobial treatment in bloodstream infections. A cohort study |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 02.11.2023 | ||
500 | |a published: Electronic-eCollection | ||
500 | |a Citation Status PubMed-not-MEDLINE | ||
520 | |a Copyright © 2023 Dietl, Boix-Palop, Gisbert, Mateu, Garreta, Xercavins, Badía, López-Sánchez, Pérez and Calbo. | ||
520 | |a Introduction: Bloodstream infections (BSI) are a major cause of mortality all over the world. Inappropriate empirical antimicrobial treatment (i-EAT) impact on mortality has been largely reported. However, information on related factors for the election of i-EAT in the treatment of BSI in adults is lacking. The aim of the study was the identification of risk-factors associated with the use of i-EAT in BSI. Methods: A retrospective, observational cohort study, from a prospective database was conducted in a 400-bed acute-care teaching hospital including all BSI episodes in adult patients between January and December 2018. The main outcome variable was EAT appropriation. Multivariate analysis using logistic regression was performed. Results: 599 BSI episodes were included, 146 (24%) received i-EAT. Male gender, nosocomial and healthcare-associated acquisition of infection, a high Charlson Comorbidity Index (CCI) score and the isolation of multidrug resistant (MDR) microorganisms were more frequent in the i-EAT group. Adequation to local guidelines' recommendations on EAT resulted in 91% of appropriate empirical antimicrobial treatment (a-EAT). Patients receiving i-EAT presented higher mortality rates at day 14 and 30 when compared to patients with a-EAT (14% vs. 6%, p = 0.002 and 22% vs. 9%, p < 0.001 respectively). In the multivariate analysis, a CCI score ≥3 (OR 1.90 (95% CI 1.16-3.12) p = 0.01) and the isolation of a multidrug resistant (MDR) microorganism (OR 3.79 (95% CI 2.28-6.30), p < 0.001) were found as independent risk factors for i-EAT. In contrast, female gender (OR 0.59 (95% CI 0.35-0.98), p = 0.04), a correct identification of clinical syndrome prior to antibiotics administration (OR 0.26 (95% CI 0.16-0.44), p < 0.001) and adherence to local guidelines (OR 0.22 (95% CI 0.13-0.38), p < 0.001) were identified as protective factors against i-EAT. Conclusion: One quarter of BSI episodes received i-EAT. Some of the i-EAT related factors were unmodifiable (male gender, CCI score ≥3 and isolation of a MDR microorganism) but others (incorrect identification of clinical syndrome before starting EAT or the use of local guidelines for EAT) could be addressed to optimize the use of antimicrobials | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a anti-bacterial agents-therapeutic use | |
650 | 4 | |a antimicrobial stewardship (ASP) intervention | |
650 | 4 | |a antimicrobial therapy | |
650 | 4 | |a bacteremia | |
650 | 4 | |a bloodstream infections (BSI) | |
650 | 4 | |a risk factors | |
700 | 1 | |a Boix-Palop, Lucía |e verfasserin |4 aut | |
700 | 1 | |a Gisbert, Laura |e verfasserin |4 aut | |
700 | 1 | |a Mateu, Aina |e verfasserin |4 aut | |
700 | 1 | |a Garreta, Gemma |e verfasserin |4 aut | |
700 | 1 | |a Xercavins, Mariona |e verfasserin |4 aut | |
700 | 1 | |a Badía, Cristina |e verfasserin |4 aut | |
700 | 1 | |a López-Sánchez, María |e verfasserin |4 aut | |
700 | 1 | |a Pérez, Josefa |e verfasserin |4 aut | |
700 | 1 | |a Calbo, Esther |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Frontiers in pharmacology |d 2010 |g 14(2023) vom: 12., Seite 1132530 |w (DE-627)NLM208568891 |x 1663-9812 |7 nnns |
773 | 1 | 8 | |g volume:14 |g year:2023 |g day:12 |g pages:1132530 |
856 | 4 | 0 | |u http://dx.doi.org/10.3389/fphar.2023.1132530 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 14 |j 2023 |b 12 |h 1132530 |